Company: TVRD
Filing Date: 2025-05-30
Form Type: S-1
Source: 0001104659-25-054853
Chunk: 318

Company: Tvardi Therapeutics, Inc.
Filing Date: 2025-05-30
Form: S-1
Chunk 318
---
 the Convertible Notes of $ million was recorded within other income (expense), net on the Company’s statement of operations for the year ended December 31, 2024. There was approximately $ million of debt issuance costs incurred in connection with the Convertible Notes. This amount was recognized within other income (expense), net in the Company’s statement of operations during the year ended December 31, 2024.

The future minimum principal payments under the Convertible Notes, if not otherwise converted pursuant to the terms above, as of December 31, 2024 are as follows:

| ​                        
 ​                        
 Years ended December 31, | ​ 
 ​ | ​         
 Principal 
 Payments  |      ​ |
|:-------------------------|:--|:----------|-------:|
| 2025                     | ​ | $         |      — |
| 2026                     | ​ |           | 28,298 |
| Thereafter               | ​ |           |      — |
| Total                    | ​ | $         | 28,298 |

9.Redeemable Convertible Preferred Stock The Company has issued Series A preferred stock and Series B preferred stock, which are collectively referred to as the Preferred Stock. As of December 31, 2024 and 2023, the Company authorized the issuance of 29,723,540shares of Preferred Stock, par value of $ 0.001per share, of which 9,499,999have been designated Series A preferred stock and 20,223,541have been designated Series B preferred stock. Series A Preferred Stock During 2018, the Company entered into the Series A preferred stock purchase agreements for 8,550,340shares of Series A preferred stock with par value of $ 0.001each at a price $ 1.00per share, or the Series A Original Issue Price, with a group of investors for net proceeds of $ 8.4million, or the Series A Financing. In addition, in connection with the closing of the Series A Financing, then outstanding convertible promissory notes of $ 0.4million were converted into 449,659shares of Series A preferred stock at the Series A Original Issue Price paid by the Series A Financing investors. Series B Preferred Stock In June 2021, the Company entered into the Series B preferred stock purchase agreements for 17,452,411shares of Series B preferred stock with par value of $ 0.001each at a price $ 3.8095per share